ONCS. H.C. Wainwright's Ram Selvaraju anticipates ONCS could apply with Phase IIb data for Breakthrough Therapy designation. Julie Lamb, Senior Editor-November 10, 2017, 10:24 AM EDT https://www.smarteranalyst.com/2017/11/10/heres-bull-sees-next-oncosec-medical-inc-oncs-back-phase-ii-combination-trial-success/